<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932980</url>
  </required_header>
  <id_info>
    <org_study_id>SPARROW 2021-01236</org_study_id>
    <nct_id>NCT04932980</nct_id>
  </id_info>
  <brief_title>Comparison of Rapid Aflibercept and Brolucizumab T&amp;E in wAMD</brief_title>
  <acronym>SPARROW</acronym>
  <official_title>Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berner Augenklinik am Lindenhofspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medignition AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Berner Augenklinik am Lindenhofspital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The currently widely established and preferred protocol for the treatment of wet age-related&#xD;
      macular degeneration includes a loading phase of three monthly injections without interim&#xD;
      adaptation or treatment according to disease activity, thereafter following a T&amp;E strategy&#xD;
      with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on&#xD;
      pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this&#xD;
      prospective explorative study is to test whether an early extension of treatment intervals&#xD;
      without a loading phase is an option without compromising functional outcomes. Based on a&#xD;
      superiority of Afl compared to Ran with regard to achieving a dry retina after one year and&#xD;
      based on studies, but in the absence of real-life experience with Bro, it seems of interest&#xD;
      to test how far Afl and Bro are comparable in terms of their potential to extend the&#xD;
      treatment intervals over 12 months, the time to dryness of the retina, and number of&#xD;
      injections. Also, it is of high clinical relevance to demonstrate efficacy with longer&#xD;
      initial treatment intervals compared to the current possibly over-treating loading-phase with&#xD;
      three four-weekly injections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two-armed, randomized, double-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of injections given until week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>number injections received by patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injections until week 104</measure>
    <time_frame>104 weeks</time_frame>
    <description>number injections received by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment failures</measure>
    <time_frame>52 weeks</time_frame>
    <description>number with treatment demand of less than 6 weeks at any time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment failures</measure>
    <time_frame>104 weeks</time_frame>
    <description>number with treatment demand of less than 6 weeks at any time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until drying of retina</measure>
    <time_frame>52 weeks</time_frame>
    <description>mean interval until absence of intra- and subretinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until drying of retina</measure>
    <time_frame>104 weeks</time_frame>
    <description>mean interval until absence of intra- and subretinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portion of eyes without disease activity</measure>
    <time_frame>52 weeks</time_frame>
    <description>% patients with absence of intra- and subretinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portion of eyes without disease activity</measure>
    <time_frame>104 weeks</time_frame>
    <description>% patients with absence of intra- and subretinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eyes under treatment intervals of ≥12 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>portion of eyes with stable disease under treatment intervals of ≥12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eyes under treatment intervals of ≥12 weeks</measure>
    <time_frame>104 weeks</time_frame>
    <description>portion of eyes with stable disease under treatment intervals of ≥12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>52 weeks</time_frame>
    <description>change of VA in logRAD from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>104 weeks</time_frame>
    <description>change of VA in logRAD from baseline to week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield thickness (CST)</measure>
    <time_frame>52 weeks</time_frame>
    <description>change from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield thickness (CST)</measure>
    <time_frame>104 weeks</time_frame>
    <description>change from baseline to week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters</measure>
    <time_frame>52 weeks</time_frame>
    <description>change from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters</measure>
    <time_frame>104 weeks</time_frame>
    <description>change from baseline to week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal treatment interval extension</measure>
    <time_frame>52 weeks</time_frame>
    <description>mean treatment interval extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal treatment interval extension</measure>
    <time_frame>104 weeks</time_frame>
    <description>mean treatment interval extension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Aflibercept ® rapid treatment extension (T&amp;E)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early treat and extend (T&amp;E) with Aflibercept ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brolucizumab ® rapid treatment extension (T&amp;E)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early treat and extend (T&amp;E) with Brolucizumab ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>administration of anti-VEGF Aflibercept (Eylea)</description>
    <arm_group_label>Aflibercept ® rapid treatment extension (T&amp;E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brolucizumab</intervention_name>
    <description>administration of anti-VEGF Brolucizumab (Beovu)</description>
    <arm_group_label>Brolucizumab ® rapid treatment extension (T&amp;E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>early treat and extend (T&amp;E)</intervention_name>
    <description>extension of treatment intervals (T&amp;E) from the beginning of treatment</description>
    <arm_group_label>Aflibercept ® rapid treatment extension (T&amp;E)</arm_group_label>
    <arm_group_label>Brolucizumab ® rapid treatment extension (T&amp;E)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active MNV secondary to nAMD, going along with clinically significant vision loss&#xD;
&#xD;
          -  Patients aged 50 years or older of all sexes&#xD;
&#xD;
          -  Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the&#xD;
             central subfield of the study eye on OCT&#xD;
&#xD;
          -  signed informed consent for this study prior to the screening visit&#xD;
&#xD;
          -  If possible: availability of a smartphone and willingness to perform self-testing with&#xD;
             the Alleye app (soft criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other cause of macular oedema&#xD;
&#xD;
          -  Structural damage to the macula precluding a visual potential&#xD;
&#xD;
          -  Optical media opacities not allowing an accurate performance of the protocol&#xD;
             examinations&#xD;
&#xD;
          -  Any intraocular surgery within three months prior to inclusion and history of any&#xD;
             vitreoretinal surgery&#xD;
&#xD;
          -  Advanced diabetic retinopathy potentially requiring any treatment within six months&#xD;
             following inclusion or history of vitreal haemorrhage&#xD;
&#xD;
          -  Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea&#xD;
&#xD;
          -  History of IVT with anti-VEGF or corticosteroids at any time in the study eye&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g., due to language problems,&#xD;
             psychological disorders, dementia, etc.&#xD;
&#xD;
          -  Significantly worse functional prognosis in the other eye or only eye&#xD;
&#xD;
          -  Women of childbearing potential not willing to use an effective method of&#xD;
             contraception during treatment and until at least 3 months after the last treatment&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any systemic auto-inflammatory and auto-immune disease requiring treatment&#xD;
&#xD;
          -  Treatment with high-dose corticosteroids (Prednisone equivalent &gt;5mg/day),&#xD;
             immunosuppressive or immunomodulatory or anti-proliferative agents for any reason&#xD;
&#xD;
          -  Inability or contraindications to undergo the investigated intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Hänsli, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berner Augenklinik am Lindenhofspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Hänsli, Dr. med.</last_name>
    <phone>+41 31 311 12 22</phone>
    <email>christof.haensli@augenklinik-bern.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justus G. Garweg, Prof. Dr. med.</last_name>
    <phone>+41 31 311 12 22</phone>
    <email>justus.garweg@augenklinik-bern.ch</email>
  </overall_contact_backup>
  <reference>
    <citation>Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28.</citation>
    <PMID>24879948</PMID>
  </reference>
  <reference>
    <citation>Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2181-2192. doi: 10.1007/s00417-020-05048-1. Epub 2021 Feb 2.</citation>
    <PMID>33528645</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wAMD</keyword>
  <keyword>Treat &amp; Extend</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Brolucizumab</keyword>
  <keyword>Loading-phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

